title: Phase II trial of vinorelbine for relapsed ovarian cancer: a Southwest Oncology Group study.
abstract: OBJECTIVE
  To assess the activity of vinorelbine in women with recurrent or resistant epithelial ovarian cancer following treatment with platinum and paclitaxel in terms of survival rate at 6 months, objective response rate (in the subset of patients with bidimensionally measurable disease), and health-related quality of life.
  
  
  METHODS
  Seventy-nine evaluable patients with progressive ovarian cancer following platinum and taxane therapy received vinorelbine 30 mg/m(2) days 1 and 8 of a 21-day treatment cycle.
  
  
  RESULTS
  Six-month survival rate for the entire group was 65% (95% CI: 54-75%) and median survival was 10.1 months (95% CI: 7.7-13.6 months). In the 71 women with measurable disease, 0 complete and 2 partial responses were observed (RR = 3%) (95% CI: 0.3-10%). Patients reported substantial symptom-related distress at baseline, which persisted, but did not worsen, during treatment. Patients also had impaired physical functioning at baseline and this continued to decline during treatment.
  
  
  CONCLUSIONS
  The 6-month survival rate achieved with salvage vinorelbine is comparable to the results obtained with other salvage therapies in patients with relapsed ovarian cancer. During the initial 10 weeks of treatment, vinorelbine did not appear to be effective in alleviating the symptom-related distress or progressive impairment of physical functioning associated with this disease.
authors.affiliation: Vanderbilt-Ingram Cancer Center, 777 Preston Research Building, Nashville, TN 37232-6307, USA. mace.rothenberg@vanderbilt.edu
authors.forename: Mace L
authors.initials: ML
authors.lastname: Rothenberg
authors.forename: P Y
authors.initials: PY
authors.lastname: Liu
authors.forename: Sharon
authors.initials: S
authors.lastname: Wilczynski
authors.forename: William A
authors.initials: WA
authors.lastname: Nahhas
authors.forename: Gaye L
authors.initials: GL
authors.lastname: Winakur
authors.forename: Caroline S
authors.initials: CS
authors.lastname: Jiang
authors.forename: Carol M
authors.initials: CM
authors.lastname: Moinpour
authors.forename: Ben
authors.initials: B
authors.lastname: Lyons
authors.forename: Geoffrey R
authors.initials: GR
authors.lastname: Weiss
authors.forename: James H
authors.initials: JH
authors.lastname: Essell
authors.forename: Harriet O
authors.initials: HO
authors.lastname: Smith
authors.forename: Maurie
authors.initials: M
authors.lastname: Markman
authors.forename: David S
authors.initials: DS
authors.lastname: Alberts
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects / Q000627:therapeutic use*; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D011788:Quality of Life; D016879:Salvage Therapy; D014747:Vinblastine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D000077235:Vinorelbine
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D014747:Vinblastine; D000077235:Vinorelbine